(alphaR)-1-(4-氯苯基)-N,N-二甲基-alpha-(2-甲基丙基)-环丁烷甲胺盐酸盐(1:1) | 154752-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (alphaR)-1-(4-氯苯基)-N,N-二甲基-alpha-(2-甲基丙基)-环丁烷甲胺盐酸盐(1:1)
• 英文名称: (+)-sibutramine hydrochloride
• 英文别名: (R)-1-(p-chlorophenyl)-α-isobutyl-N,N-dimethylcyclobutanemethylamine hydrochloride；R-sibutramine；(R)-(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride；(R)-Sibutramine hydrochloride；(1R)-1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine;hydrochloride
• CAS: 154752-45-1
• 化学式: C₁₇H₂₆ClN*ClH
• 分子量: 316.314
• InChiKey: UWAOJIWUVCMBAZ-PKLMIRHRSA-N

物化性质

• 溶解度：
  氯仿（微溶）、甲醇（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  5.16
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  盐酸西布曲明 在 randomly methylated β-cyclodextrin 作用下， 以 aq. phosphate buffer 为溶剂， 15.0 ℃ 、3.0 kPa 条件下， 生成 (S)-1-(p-chlorophenyl)-α-isobutyl-N,N-dimethylcyclobutanemethylamine hydrochloride 、 (alphaR)-1-(4-氯苯基)-N,N-二甲基-alpha-(2-甲基丙基)-环丁烷甲胺盐酸盐(1:1)
  参考文献：
  名称：

  Enantiomeric Separation of Sibutramine by Capillary Zone Electrophoresis

  摘要：

  The chiral separation of sibutramine enantiomers was resolved succesfully by capillary zone electrophoresis using cyclodextrins (CDs) as chiral selectors. A complex screening of several different native and derivatized, neutral and ionized cyclodextrine derivatives was performed. The effects of buffer type, concentration and pH, cyclodextrin type and concentration, applied voltage, capillary temperature and injection parameters on the chiral resolution were examined. The best results on a very short fused silica capillary of 30 cm x 50 mu m were obtained using a 50 mmol L-1 phosphate buffer containing 10 mmol L-1 randomly methylated beta-CD at a pH of 4.5, 15 kV of voltage, temperature of 15 degrees C, injection parameters of 30 mbar s(-1) and ultraviolet (UV) detection at 220 nm. The analytical performances of the optimized method were verified in terms of linearity, precision and robustness, and limit of detection and quantification were calculated.

  DOI：

  10.5935/0103-5053.20150359

文献信息

• Therapeutic agents
  申请人：——

  公开号：US20030130355A1

  公开（公告）日：2003-07-10

  The present invention provides a method of treating and preventing obesity and related co-morbid conditions comprising the administration of a therapeutically effective amount of one or more monoamine reuptake inhibitors which are serotonin reuptake inhibitors and/or noradrenaline reuptake inhibitors and a 5-HT 1A agonist to a patient in need thereof.

  本发明提供了一种治疗和预防肥胖及相关共病症的方法，包括向需要此类治疗的患者给予一种或多种单胺再摄取抑制剂，这些抑制剂是选择性5-羟色胺再摄取抑制剂和/或去甲肾上腺素再摄取抑制剂，以及一种5-HT1A受体激动剂的治疗有效量。